RU2012120691A - Новый режим дозирования и способ лечения - Google Patents
Новый режим дозирования и способ лечения Download PDFInfo
- Publication number
- RU2012120691A RU2012120691A RU2012120691/15A RU2012120691A RU2012120691A RU 2012120691 A RU2012120691 A RU 2012120691A RU 2012120691/15 A RU2012120691/15 A RU 2012120691/15A RU 2012120691 A RU2012120691 A RU 2012120691A RU 2012120691 A RU2012120691 A RU 2012120691A
- Authority
- RU
- Russia
- Prior art keywords
- day
- weeks
- dosage regimen
- administered
- cancer
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims abstract 46
- 238000011282 treatment Methods 0.000 title claims abstract 15
- 238000001802 infusion Methods 0.000 claims abstract 26
- 206010028980 Neoplasm Diseases 0.000 claims abstract 20
- 239000003246 corticosteroid Substances 0.000 claims abstract 17
- 201000011510 cancer Diseases 0.000 claims abstract 15
- 206010033128 Ovarian cancer Diseases 0.000 claims abstract 5
- 206010061535 Ovarian neoplasm Diseases 0.000 claims abstract 5
- 206010041067 Small cell lung cancer Diseases 0.000 claims abstract 5
- 229960001334 corticosteroids Drugs 0.000 claims abstract 5
- 230000000955 neuroendocrine Effects 0.000 claims abstract 5
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims abstract 5
- 230000000069 prophylactic effect Effects 0.000 claims abstract 5
- 208000000587 small cell lung carcinoma Diseases 0.000 claims abstract 5
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims abstract 5
- 229960003957 dexamethasone Drugs 0.000 claims 16
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 claims 16
- 229960004562 carboplatin Drugs 0.000 claims 10
- 190000008236 carboplatin Chemical compound 0.000 claims 10
- VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical group COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 claims 10
- 229960005420 etoposide Drugs 0.000 claims 10
- 229940124623 antihistamine drug Drugs 0.000 claims 8
- 239000000739 antihistaminic agent Substances 0.000 claims 8
- 210000004027 cell Anatomy 0.000 claims 8
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 claims 8
- 210000000822 natural killer cell Anatomy 0.000 claims 8
- 238000011394 anticancer treatment Methods 0.000 claims 6
- 229960004942 lenalidomide Drugs 0.000 claims 6
- GOTYRUGSSMKFNF-UHFFFAOYSA-N lenalidomide Chemical group C1C=2C(N)=CC=CC=2C(=O)N1C1CCC(=O)NC1=O GOTYRUGSSMKFNF-UHFFFAOYSA-N 0.000 claims 6
- VHRSUDSXCMQTMA-PJHHCJLFSA-N 6alpha-methylprednisolone Chemical compound C([C@@]12C)=CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2[C@@H](O)C[C@]2(C)[C@@](O)(C(=O)CO)CC[C@H]21 VHRSUDSXCMQTMA-PJHHCJLFSA-N 0.000 claims 4
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims 4
- 206010003571 Astrocytoma Diseases 0.000 claims 4
- 206010006187 Breast cancer Diseases 0.000 claims 4
- 208000026310 Breast neoplasm Diseases 0.000 claims 4
- VOVIALXJUBGFJZ-KWVAZRHASA-N Budesonide Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1C[C@H]3OC(CCC)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@@H]2O VOVIALXJUBGFJZ-KWVAZRHASA-N 0.000 claims 4
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 4
- 206010025323 Lymphomas Diseases 0.000 claims 4
- 208000002030 Merkel cell carcinoma Diseases 0.000 claims 4
- 208000034578 Multiple myelomas Diseases 0.000 claims 4
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 claims 4
- 206010029260 Neuroblastoma Diseases 0.000 claims 4
- 206010029266 Neuroendocrine carcinoma of the skin Diseases 0.000 claims 4
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 4
- 206010039491 Sarcoma Diseases 0.000 claims 4
- 208000008383 Wilms tumor Diseases 0.000 claims 4
- 229940092705 beclomethasone Drugs 0.000 claims 4
- NBMKJKDGKREAPL-DVTGEIKXSA-N beclomethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(Cl)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O NBMKJKDGKREAPL-DVTGEIKXSA-N 0.000 claims 4
- 229960004436 budesonide Drugs 0.000 claims 4
- 208000002458 carcinoid tumor Diseases 0.000 claims 4
- 208000017763 cutaneous neuroendocrine carcinoma Diseases 0.000 claims 4
- ZZVUWRFHKOJYTH-UHFFFAOYSA-N diphenhydramine Chemical compound C=1C=CC=CC=1C(OCCN(C)C)C1=CC=CC=C1 ZZVUWRFHKOJYTH-UHFFFAOYSA-N 0.000 claims 4
- 229960000520 diphenhydramine Drugs 0.000 claims 4
- 229960000676 flunisolide Drugs 0.000 claims 4
- 229960000289 fluticasone propionate Drugs 0.000 claims 4
- WMWTYOKRWGGJOA-CENSZEJFSA-N fluticasone propionate Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@@H](C)[C@@](C(=O)SCF)(OC(=O)CC)[C@@]2(C)C[C@@H]1O WMWTYOKRWGGJOA-CENSZEJFSA-N 0.000 claims 4
- 210000001035 gastrointestinal tract Anatomy 0.000 claims 4
- 229960000890 hydrocortisone Drugs 0.000 claims 4
- 229950003526 lorvotuzumab mertansine Drugs 0.000 claims 4
- 210000004072 lung Anatomy 0.000 claims 4
- 201000005296 lung carcinoma Diseases 0.000 claims 4
- 229960004584 methylprednisolone Drugs 0.000 claims 4
- 201000008026 nephroblastoma Diseases 0.000 claims 4
- 208000007538 neurilemmoma Diseases 0.000 claims 4
- 201000011519 neuroendocrine tumor Diseases 0.000 claims 4
- 201000008968 osteosarcoma Diseases 0.000 claims 4
- 208000021010 pancreatic neuroendocrine tumor Diseases 0.000 claims 4
- 229960005205 prednisolone Drugs 0.000 claims 4
- OIGNJSKKLXVSLS-VWUMJDOOSA-N prednisolone Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OIGNJSKKLXVSLS-VWUMJDOOSA-N 0.000 claims 4
- 229960004618 prednisone Drugs 0.000 claims 4
- XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 claims 4
- MIXMJCQRHVAJIO-TZHJZOAOSA-N qk4dys664x Chemical compound O.C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]2(C)C[C@@H]1O.C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]2(C)C[C@@H]1O MIXMJCQRHVAJIO-TZHJZOAOSA-N 0.000 claims 4
- 229960002117 triamcinolone acetonide Drugs 0.000 claims 4
- YNDXUCZADRHECN-JNQJZLCISA-N triamcinolone acetonide Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@@H]2O YNDXUCZADRHECN-JNQJZLCISA-N 0.000 claims 4
- 241000124008 Mammalia Species 0.000 claims 1
- 239000002246 antineoplastic agent Substances 0.000 claims 1
- 229940041181 antineoplastic drug Drugs 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/77—Internalization into the cell
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Immunology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Engineering & Computer Science (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US25380409P | 2009-10-21 | 2009-10-21 | |
| US61/253,804 | 2009-10-21 | ||
| PCT/US2010/053579 WO2011050180A1 (en) | 2009-10-21 | 2010-10-21 | Novel dosing regimen and method of treatment |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2012120691A true RU2012120691A (ru) | 2013-11-27 |
Family
ID=43898626
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2012120691/15A RU2012120691A (ru) | 2009-10-21 | 2010-10-21 | Новый режим дозирования и способ лечения |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20110097345A1 (OSRAM) |
| EP (1) | EP2490715A4 (OSRAM) |
| JP (1) | JP2013508400A (OSRAM) |
| KR (1) | KR20120094472A (OSRAM) |
| CN (1) | CN102630165A (OSRAM) |
| AU (1) | AU2010310577A1 (OSRAM) |
| BR (1) | BR112012009250A2 (OSRAM) |
| CA (1) | CA2775806A1 (OSRAM) |
| IL (1) | IL219279A0 (OSRAM) |
| IN (1) | IN2012DN02826A (OSRAM) |
| MX (1) | MX2012004406A (OSRAM) |
| RU (1) | RU2012120691A (OSRAM) |
| WO (1) | WO2011050180A1 (OSRAM) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9486408B2 (en) | 2005-12-01 | 2016-11-08 | University Of Massachusetts Lowell | Botulinum nanoemulsions |
| AU2011207362B2 (en) * | 2010-01-21 | 2013-10-17 | Immunogen, Inc. | Compositions and methods for treatment of ovarian cancer |
| EP2524929A1 (en) * | 2011-05-17 | 2012-11-21 | Sanofi | Use of anti-CD19 maytansinoid immunoconjugate antibody for the treatment of CD19+ B-cell malignancies syptoms |
| WO2014018563A2 (en) * | 2012-07-23 | 2014-01-30 | The Board Of Trustees Of The Leland Stanford Junior University | Methods for the treatment of cancer |
| WO2014052876A1 (en) * | 2012-09-28 | 2014-04-03 | Immunogen Inc. | Methods for increasing efficacy of cd56- based therapy |
| WO2014089177A2 (en) | 2012-12-04 | 2014-06-12 | Massachusetts Institute Of Technology | Compounds, conjugates and compositions of epipolythiodiketopiperazines and polythiodiketopiperazines |
| SG11201509043RA (en) * | 2013-05-14 | 2015-12-30 | Immunogen Inc | Anti-folr1 immunoconjugate dosing regimens |
| LT3055332T (lt) * | 2013-10-08 | 2020-04-10 | Immunogen, Inc. | Anti-folr1 imunokonjugato dozavimo režimai |
| CN106456748A (zh) | 2014-01-08 | 2017-02-22 | 小利兰·斯坦福大学托管委员会 | 小细胞肺癌的靶向疗法 |
| AU2015282627B2 (en) | 2014-06-30 | 2020-04-02 | Glykos Finland Oy | Saccharide derivative of a toxic payload and antibody conjugates thereof |
| US10918627B2 (en) | 2016-05-11 | 2021-02-16 | Massachusetts Institute Of Technology | Convergent and enantioselective total synthesis of Communesin analogs |
| JP6998938B2 (ja) * | 2016-08-10 | 2022-02-04 | セルジーン クオンティセル リサーチ，インク． | 再発性および／または難治性の固形腫瘍および非ホジキンリンパ腫の処置 |
| KR102487144B1 (ko) | 2016-11-21 | 2023-01-12 | 에이리온 테라퓨틱스, 인코포레이티드 | 큰 물질의 경피 전달 |
| WO2018209239A1 (en) | 2017-05-11 | 2018-11-15 | Massachusetts Institute Of Technology | Potent agelastatin derivatives as modulators for cancer invasion and metastasis |
| US10640508B2 (en) | 2017-10-13 | 2020-05-05 | Massachusetts Institute Of Technology | Diazene directed modular synthesis of compounds with quaternary carbon centers |
| AU2019294510A1 (en) * | 2018-06-26 | 2021-01-21 | Immunogen, Inc. | Immunoconjugates targeting ADAM9 and methods of use thereof |
| US11535634B2 (en) | 2019-06-05 | 2022-12-27 | Massachusetts Institute Of Technology | Compounds, conjugates, and compositions of epipolythiodiketopiperazines and polythiodiketopiperazines and uses thereof |
| US20230322933A1 (en) * | 2020-06-04 | 2023-10-12 | Bioinvent International Ab | Model for prediction of tolerability issues in connection with intravenous administration of therapeutic antibodies |
| US12030888B2 (en) | 2021-02-24 | 2024-07-09 | Massachusetts Institute Of Technology | Himastatin derivatives, and processes of preparation thereof, and uses thereof |
| WO2024230793A1 (en) * | 2023-05-10 | 2024-11-14 | Nanjing Legend Biotech Co., Ltd. | Chimeric antigen receptors and methods of use thereof |
| CN120053673A (zh) * | 2025-02-11 | 2025-05-30 | 暨南大学 | 纳米前药及其制备方法和用途 |
| CN120173115A (zh) * | 2025-05-20 | 2025-06-20 | 苏州欣协生物科技有限公司 | 一种抗人cd56蛋白工程抗体及其制备方法 |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5208020A (en) * | 1989-10-25 | 1993-05-04 | Immunogen Inc. | Cytotoxic agents comprising maytansinoids and their therapeutic use |
| US5639641A (en) * | 1992-09-09 | 1997-06-17 | Immunogen Inc. | Resurfacing of rodent antibodies |
| US7303749B1 (en) * | 1999-10-01 | 2007-12-04 | Immunogen Inc. | Compositions and methods for treating cancer using immunoconjugates and chemotherapeutic agents |
| EP2266607A3 (en) * | 1999-10-01 | 2011-04-20 | Immunogen, Inc. | Immunoconjugates for treating cancer |
| MXPA03012022A (es) * | 2001-09-20 | 2005-07-01 | Cornell Res Foundation Inc | Metodos y composiciones para tratar o prevenir padecimientos de la piel, utilizando agentes de enlace especificos para el antigeno de membrana especifico de prostata. |
| US20040126379A1 (en) * | 2002-08-21 | 2004-07-01 | Boehringer Ingelheim International Gmbh | Compositions and methods for treating cancer using cytotoxic CD44 antibody immunoconjugates and chemotherapeutic agents |
| CN1816356A (zh) * | 2003-05-14 | 2006-08-09 | 免疫原公司 | 药物缀合物组合物 |
| WO2005000230A2 (en) * | 2003-06-05 | 2005-01-06 | Charles Achkar | Methods of treating hyperproliferative cell disorders |
| US8101720B2 (en) * | 2004-10-21 | 2012-01-24 | Xencor, Inc. | Immunoglobulin insertions, deletions and substitutions |
| ZA200708694B (en) * | 2005-04-15 | 2009-01-28 | Immunogen Inc | Elimination of heterogeneous or mixed cell population in tumors |
| NZ576122A (en) * | 2006-09-26 | 2012-09-28 | Genmab As | Anti-cd38 plus corticosteroids plus a non-corticosteroid chemotherapeutic for treating tumors |
| AU2009271401A1 (en) * | 2008-06-16 | 2010-01-21 | Immunogen Inc. | Novel synergistic effects |
| AU2011207362B2 (en) * | 2010-01-21 | 2013-10-17 | Immunogen, Inc. | Compositions and methods for treatment of ovarian cancer |
| WO2012138537A1 (en) * | 2011-04-01 | 2012-10-11 | Immunogen, Inc. | Compositions and methods for treatment of ovarian, peritoneal, and fallopian tube cancer |
-
2010
- 2010-10-21 WO PCT/US2010/053579 patent/WO2011050180A1/en not_active Ceased
- 2010-10-21 EP EP10825683.5A patent/EP2490715A4/en not_active Withdrawn
- 2010-10-21 CN CN2010800455971A patent/CN102630165A/zh active Pending
- 2010-10-21 BR BR112012009250A patent/BR112012009250A2/pt not_active IP Right Cessation
- 2010-10-21 IN IN2826DEN2012 patent/IN2012DN02826A/en unknown
- 2010-10-21 JP JP2012535373A patent/JP2013508400A/ja not_active Withdrawn
- 2010-10-21 AU AU2010310577A patent/AU2010310577A1/en not_active Abandoned
- 2010-10-21 US US12/909,697 patent/US20110097345A1/en not_active Abandoned
- 2010-10-21 MX MX2012004406A patent/MX2012004406A/es not_active Application Discontinuation
- 2010-10-21 RU RU2012120691/15A patent/RU2012120691A/ru unknown
- 2010-10-21 KR KR1020127008847A patent/KR20120094472A/ko not_active Withdrawn
- 2010-10-21 CA CA2775806A patent/CA2775806A1/en not_active Abandoned
-
2012
- 2012-04-19 IL IL219279A patent/IL219279A0/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| US20110097345A1 (en) | 2011-04-28 |
| IN2012DN02826A (OSRAM) | 2015-07-24 |
| KR20120094472A (ko) | 2012-08-24 |
| MX2012004406A (es) | 2012-05-08 |
| AU2010310577A1 (en) | 2012-04-19 |
| CN102630165A (zh) | 2012-08-08 |
| EP2490715A4 (en) | 2013-06-26 |
| CA2775806A1 (en) | 2011-04-28 |
| IL219279A0 (en) | 2012-06-28 |
| BR112012009250A2 (pt) | 2017-06-20 |
| WO2011050180A1 (en) | 2011-04-28 |
| EP2490715A1 (en) | 2012-08-29 |
| JP2013508400A (ja) | 2013-03-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2012120691A (ru) | Новый режим дозирования и способ лечения | |
| Cho et al. | Cancer stem cells as a potential target to overcome multidrug resistance | |
| JP2013508400A5 (OSRAM) | ||
| Sumanasuriya et al. | Treatment of advanced prostate cancer—A review of current therapies and future promise | |
| US20220323475A1 (en) | Combination therapy for cancer | |
| Li et al. | Ergosterol peroxide activates Foxo3-mediated cell death signaling by inhibiting AKT and c-Myc in human hepatocellular carcinoma cells | |
| US20230149436A1 (en) | Combination therapy | |
| AU2015418015B2 (en) | Combination therapy | |
| JP2018065859A (ja) | 癌を治療するための方法及び組成物 | |
| CN106470672A (zh) | 包括吉西他滨前药的制剂 | |
| AU2015278899A1 (en) | Gemcitabine prodrugs | |
| IL272095B (en) | Cortexolone 17alpha-valerate for use in the treatment of epithelial tumor diseases | |
| Misir et al. | circRNAs in drug resistance of breast cancer | |
| JP2017516802A5 (OSRAM) | ||
| Gordon et al. | Success using tacrolimus in patients with proliferative and membranous lupus nephritis and refractory proteinuria | |
| CN116490165A (zh) | 阿比特龙前药 | |
| Schwarzlmueller et al. | Steroid hormones as modulators of anti-tumoural immunity | |
| CN107773556A (zh) | 一种具有抗肿瘤药物功效的联合用药物 | |
| Liang et al. | Role of the AKT signaling pathway in regulating tumor-associated macrophage polarization and in the tumor microenvironment: A review | |
| US20200197430A1 (en) | Combination Therapy | |
| CN119136813A (zh) | 阿比特龙前药 | |
| McAuley et al. | Chromosome 1 Alterations in Multiple Myeloma: Considerations for Precision Therapy | |
| JP2020172471A (ja) | ヒト化抗ヒトｃｄ２６抗体を含有する医薬組成物 | |
| KR20240134470A (ko) | 글루코코르티코이드계 화합물을 포함하는 암의 예방 또는 치료용 약학적 조성물 | |
| Schmidt | Novel therapeutic approaches to overcome acquired resistance to enzalutamide in patients with advanced prostate cancer |